Innovations in Prostate Cancer: Unveiling Novel Therapies and the Role of the Specialty Pharmacist

This activity was originally broadcast in conjunction with Asembia Specialty Pharmacy Summit 2024.

Program Description

Prostate cancer, a disease driven by androgens, is the second leading cause of cancer-related death in men in the US. Chemical castration through androgen deprivation therapy is a key treatment strategy to lower production of testosterone, a principal androgen. Emerging second-generation antiandrogens and PARP inhibitors have proven beneficial in treating different types of prostate cancer. Although these therapies show a survival benefit, the 5-year survival rate for patients with metastatic castration-resistant prostate cancer remains low. Pharmacists counsel patients living with prostate cancer on different treatment options, considerations for cost of care, and strategies for medication adherence. Pharmacists also communicate with clinicians to suggest therapies to mitigate adverse effects and improve the patient’s quality of life. This activity will explore indications and considerations for emerging therapies, as well as the pharmacist’s role in monitoring and addressing treatment-related toxicities to allow treatment continuation. This activity will keep pharmacists up to date on different combination regimens for treating prostate cancer so they can help individuals achieve favorable outcomes.

Target audience: Oncology and specialty pharmacists

Type of activity: Application
Release date: May 17, 2024
Expiration date: May 17, 2025

Time to complete activity: 1.5 hours

Learner level: Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explore the pharmacology, indications, special considerations, and current role of oral therapies in patients with prostate cancer
• Examine recent clinical and safety evidence to support guideline recommendations on current and emerging therapies for patients with prostate cancer
• Employ specialty pharmacy-driven strategies that consider factors such as administration, safety profiles, comorbidities, and patient goals to improve tolerability and adherence to oral agents used to treat prostate cancer

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-24-134-H01-P. The activity is available for CE credit through May 17, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, has the following financial relationships with commercial interests to disclose:
Grant/Research Support: Janssen, AstraZeneca

Consultant: Regeneron, GSK

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Sherry L. Vogt, PharmD, BCOP

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Daphne Davis, PharmD, BCOP; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.


Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms